LAGE-3 Inhibitors
Inhibitors of LAGE-3 exert their effects through targeting specific signaling pathways and cellular processes that play a pivotal role in its functional activity. These inhibitors are primarily focused on disrupting the cell cycle, a critical process that may be intimately connected with the function of LAGE-3. By specifically inhibiting cyclin-dependent kinases (CDKs), which serve as key regulators of cell cycle progression, the inhibitors can cause a cessation of the cell cycle, particularly in the G1 phase, and therefore potentially decrease the stability and activity of LAGE-3. The assumption underlying the use of these inhibitors is that LAGE-3 is either directly involved in cell cycle regulation or its activity is influenced by proteins whose stability and function are cell cycle-dependent. The inhibition of these kinases could therefore indirectly prevent LAGE-3 from exerting its function, thereby effectively reducing its activity within the cell.
The compounds identified as inhibitors manage to achieve this indirect suppression of LAGE-3 through a variety of mechanisms, all converging on the inhibition of CDK activity. By halting CDKs, these inhibitors disrupt the phosphorylation states of proteins involved in cell cycle control, which could subsequently affect proteins that interact with or regulate LAGE-3, assuming that LAGE-3's function is tied to these cell cycle-regulated processes. The spectrum of CDK inhibitors includes selective inhibitors of CDK2, as well as those targeting CDK4/6, which are particularly implicated in G1 phase regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor. By inhibiting CDKs, it can lead to the suppression of cell cycle progression, potentially decreasing the stability and activity of LAGE-3, which may have cell cycle-related functions. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a CDK inhibitor that can halt the cell cycle. By impeding the cell cycle, it could indirectly inhibit LAGE-3 activity if LAGE-3 is involved in cell cycle-dependent processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a potent CDK inhibitor that may disrupt the phosphorylation states of proteins involved in the cell cycle, potentially affecting the function of LAGE-3 if it is associated with these proteins. | ||||||
Indirubin | 479-41-4 | sc-201531 sc-201531A | 5 mg 25 mg | $114.00 $525.00 | 4 | |
Indirubin, a CDK inhibitor, could alter the activity of LAGE-3 by affecting the phosphorylation state of downstream proteins that interact with or regulate LAGE-3, leading to its functional inhibition. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $122.00 $514.00 | 1 | |
Butyrolactone I specifically inhibits CDK2, which could indirectly result in the inhibition of LAGE-3 function if LAGE-3 is involved in the cell cycle mechanisms regulated by CDK2. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs, particularly affecting cell cycle phases. Its inhibition of CDKs might lead to decreased activity of LAGE-3 through cell cycle arrest if LAGE-3 is cell cycle-dependent. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4/6, which could lead to cell cycle arrest in the G1 phase, potentially inhibiting LAGE-3 if it is involved in downstream signaling from CDK4/6. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits CDK4/6 and could decrease the function of LAGE-3 by causing G1 phase arrest in cells, assuming LAGE-3 is regulated by or associated with cell cycle progression. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is a CDK4/6 inhibitor that could lead to the inhibition of LAGE-3 by causing cell cycle arrest, assuming that LAGE-3 activity is dependent on the cell cycle states regulated by CDK4/6. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs and could lead to a decrease in LAGE-3 function by disrupting the cell cycle and thereby affecting any cell cycle-associated activity of LAGE-3. | ||||||